14. HIV Integrase Inhibitors: From Diketo Acids to Heterocyclic Templates: History of HIV Integrase Medicinal Chemistry at Merck West Point and Merck Rome (IRBM) Leading to Discovery of Raltegravir
- Nouri Neamati
Published Online: 28 SEP 2011
DOI: 10.1002/9781118015377.ch14
Copyright © 2011 John Wiley & Sons, Inc.
Book Title

HIV-1 Integrase: Mechanism and Inhibitor Design
Additional Information
How to Cite
Egbertson, M. S., Anthony, N. J. and Summa, V. (2011) HIV Integrase Inhibitors: From Diketo Acids to Heterocyclic Templates: History of HIV Integrase Medicinal Chemistry at Merck West Point and Merck Rome (IRBM) Leading to Discovery of Raltegravir, in HIV-1 Integrase: Mechanism and Inhibitor Design (ed N. Neamati), John Wiley & Sons, Inc., Hoboken, NJ, USA. doi: 10.1002/9781118015377.ch14
Editor Information
Department of Pharmacology and Pharmaceutical Sciences, University of Southern California, School of Pharmacy, Los Angeles, California, USA
Publication History
- Published Online: 28 SEP 2011
- Published Print: 9 SEP 2011
ISBN Information
Print ISBN: 9780470184745
Online ISBN: 9781118015377
- Summary
- Chapter
- References
Keywords:
- HIV integrase inhibitors;
- heterocyclic rings;
- polar heterocyclic substituents, 5-position
Summary
This chapter contains sections titled:
Introduction
First Leads
SAR of Diketo Acid Series
Diketo Acid Is Replaced
SAR of Diaryl Diketones
Replacement of Diaryl Diketone
Combination of 1,6-Naphthyridine and Amide to Give New Lead Structures
Another Template
Proof of Concept
Search for More Potent Analog of 16-2: 5-Position Heterocycles and 5-Position Amides
Development of Potent Analog of 16-2
Development of IRBM Hydroxypyrimidinones: Raltegravir
Summary: Diketo Acids as Leads for Integrase Inhibitor Development
Acknowledgments
References
